Floatz logo

Rivoceranib

Advanced Gastric Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.Small moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

282 Active assets in the Advanced Gastric Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Shenzhen Xinhe Biomedical
Phase 4BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

Rivoceranib is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
72 / 100
View asset →
ApatinibDormant
BB
Indicative ·
70 / 100
View asset →
cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →